Olympus Medical Follows The Patient Pathway In New Strategic Plan
Value Creation Drive Is Underway Says CEO Takeuchi
Having divested non-medical imaging a year ago, Olympus Corp is putting its foot to the floor in refocusing on its medical portfolio. It has set global ambitions of strengthening its coverage of unmet needs and of playing a major role in reshaping health care delivery.
You may also be interested in...
Listing all-time high medtech IPO and M&A activity, Silicon Valley Bank’s 2021 health care investments and exits report made good reading after the market uncertainties induced by the pandemic a year earlier. But where does the sector go now after such a sterling year?
The performances of the leading medtechs in the first year of the COVID-19 pandemic were impossible to compare and certainly unrepresentative of normal business cycles and competitive activity. Elective care was largely put on hold and emergency needs boosted exceptional demand for certain product types. More than anything else, 2020 tested management skills and planning.
A medical company that has some other businesses – that is the shorthand description that Olympus Corp. of the Americas president and CEO Nacho Abia ascribes to a group that has emerged from difficult times with a new strategy, new structure and new determination. Targeted deals and M&A remain as important as ever to the group as it embarks, somewhat reinvented, on a new five-year plan.